{
    "status": "ok",
    "totalResults": 5,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "HC Wainwright Comments on UroGen Pharma Ltd.\u2019s FY2023 Earnings (NASDAQ:URGN)",
            "description": "UroGen Pharma Ltd. (NASDAQ:URGN \u2013 Free Report) \u2013 Equities research analysts at HC Wainwright increased their FY2023 earnings per share (EPS) estimates for shares of UroGen Pharma in a research note issued to investors on Wednesday, November 15th. HC Wainwrigh\u2026",
            "url": "https://www.etfdailynews.com/2023/11/17/hc-wainwright-comments-on-urogen-pharma-ltd-s-fy2023-earnings-nasdaqurgn/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/urogen-pharma-ltd-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-17T12:14:44Z",
            "content": "UroGen Pharma Ltd. (NASDAQ:URGN \u2013 Free Report) \u2013 Equities research analysts at HC Wainwright increased their FY2023 earnings per share (EPS) estimates for shares of UroGen Pharma in a research note i\u2026 [+3737 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Stonepine Capital Management LLC Decreases Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)",
            "description": "Stonepine Capital Management LLC decreased its position in UroGen Pharma Ltd. (NASDAQ:URGN \u2013 Free Report) by 36.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 448,508 share\u2026",
            "url": "https://www.etfdailynews.com/2023/11/27/stonepine-capital-management-llc-decreases-holdings-in-urogen-pharma-ltd-nasdaqurgn/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/urogen-pharma-ltd-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-27T18:40:56Z",
            "content": "Stonepine Capital Management LLC decreased its position in UroGen Pharma Ltd. (NASDAQ:URGN \u2013 Free Report) by 36.1% in the 2nd quarter, according to the company in its most recent filing with the Secu\u2026 [+4265 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023",
            "description": "(marketscreener.com) \nConference Call and Webcast Scheduled for Tuesday, November 14, 2023 at 10:00 AM ET\n\nhttps://www.marketscreener.com/quote/stock/UROGEN-PHARMA-LTD-34790020/news/UroGen-Pharma-to-Report-Third-Quarter-2023-Financial-Results-on-Tuesday-Novem\u2026",
            "url": "https://www.marketscreener.com/quote/stock/UROGEN-PHARMA-LTD-34790020/news/UroGen-Pharma-to-Report-Third-Quarter-2023-Financial-Results-on-Tuesday-November-14-2023-45260212/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-07T13:13:01Z",
            "content": "Conference Call and Webcast Scheduled for Tuesday, November 14, 2023 at 10:00 AM ET\r\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative soluti\u2026 [+1570 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "UroGen Pharma (URGN) to Release Earnings on Tuesday",
            "description": "UroGen Pharma (NASDAQ:URGN \u2013 Get Free Report) will be releasing its earnings data before the market opens on Tuesday, November 14th. Analysts expect UroGen Pharma to post earnings of ($0.89) per share for the quarter. UroGen Pharma (NASDAQ:URGN \u2013 Get Free Rep\u2026",
            "url": "https://www.etfdailynews.com/2023/11/08/urogen-pharma-urgn-to-release-earnings-on-tuesday/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/urogen-pharma-ltd-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-08T13:32:44Z",
            "content": "UroGen Pharma (NASDAQ:URGN \u2013 Get Free Report) will be releasing its earnings data before the market opens on Tuesday, November 14th. Analysts expect UroGen Pharma to post earnings of ($0.89) per shar\u2026 [+3986 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology",
            "description": "(marketscreener.com) \n\nResults from the pivotal Phase 3 ENVISION trial studying primary chemoablation with UGN-102 for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer will be presented as a late-\u2026",
            "url": "https://www.marketscreener.com/quote/stock/UROGEN-PHARMA-LTD-34790020/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-13T13:03:01Z",
            "content": "<table><tr><th>Date</th><th>Price</th><th>Change</th><th>Volume</th></tr>\r\n<tr><td>\r\n 23-11-10\r\n </td><td>11.46</td><td>-0.09%</td><td>\r\n 210,418 </td></tr><tr><td>\r\n 23-11-09\r\n </td><td>11.47</td><t\u2026 [+363 chars]"
        }
    ]
}